5-Amino-1MQ vs Vilon.

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule, substrate-site inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). Despite being grouped with "peptides" in the research-chemical marketplace, it is not a peptide at all but a methylquinolinium heterocyclic salt that emerged from academic medicinal-chemistry work at the University of Texas aimed at producing membrane-permeable NNMT inhibitors. It is an investigational research compound, not an approved drug.

Vilon is a synthetic dipeptide, L-lysyl-L-glutamate (Lys-Glu), one of the short peptide bioregulators developed by Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology in Russia. It was designed as a minimal synthetic analogue reflecting active sequences found in thymic peptide preparations such as thymalin. Despite its very small size, it is promoted as a geroprotective and immunomodulatory agent. It is a research compound with no approved medical use.

NNMT is a cytosolic enzyme that transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, generating 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). Because nicotinamide is the precursor for NAD+ salvage, high NNMT activity in adipose tissue is thought to drain nicotinamide away from NAD+ synthesis and consume SAM. By occupying the nicotinamide substrate site, 5-Amino-1MQ lowers cellular 1-MNA and is proposed to spare nicotinamide for NAD+ regeneration and free up SAM-cycle methylation capacity. The downstream hypothesis (elevated NAD+ activating sirtuins/AMPK to favor energy expenditure over lipid storage) is mechanistically plausible but is largely inferred from cell and rodent work rather than directly demonstrated in humans.

Vilon is hypothesized to act as a gene-regulating bioregulator: proponents propose that the dipeptide can penetrate cells, bind DNA and histones, and alter chromatin accessibility to switch on genes silenced with aging. In immune tissue it is reported to activate T-helper cells and modulate age-associated immune changes. Some microarray studies from the originating group describe changes in gene expression in mouse tissues after vilon exposure. As with other Khavinson peptides, these mechanistic claims rest mainly on the developing laboratory's own experiments rather than on independent confirmation.

The core evidence is preclinical. Neelakantan et al. (Biochemical Pharmacology, 2018) reported that methylquinolinium NNMT inhibitors including 5-Amino-1MQ were membrane-permeable, relatively selective, lowered intracellular 1-MNA, and reduced lipogenesis in 3T3-L1 adipocytes; in diet-induced obese mice on a high-fat diet, systemic NNMT-inhibitor treatment significantly reduced body weight, white adipose mass, and adipocyte size and lowered plasma total cholesterol without changing food intake or producing observable adverse effects. Supporting context comes from Ehebauer et al. (Life Sciences, 2020) on glucose-dependent NNMT regulation in adipocytes, and Dimet-Wiley et al. (Scientific Reports, 2022) combining NNMT inhibition with calorie restriction in obese mice. There are no published human clinical trials, and no human pharmacokinetic or efficacy data for 5-Amino-1MQ have been reported. The human-vs-animal gap here is large and should not be glossed over.

The vilon evidence base is almost entirely preclinical and comes from Vladimir Khavinson, Vladimir Anisimov and colleagues, published largely in Russian journals. Reported findings include inhibition of spontaneous and chemically induced tumors and increased lifespan in mice, plus effects on biological-age markers and gene expression. These are animal and cell studies from a single research tradition; there are essentially no independent Western randomized controlled trials or robust human efficacy data. To state it plainly: there are no human clinical trials of vilon in the mainstream indexed literature, so every claim about human benefit is an extrapolation from rodent and cell-culture work. The animal studies are typically conducted in inbred mouse strains at a single institution, with lifespan and tumor incidence as endpoints, without blinded pathology review, without preregistration, and without replication in a second laboratory using a different animal facility and diet, all of which are known to influence rodent lifespan results. The mechanistic work is similar in character: microarray and cell-culture studies attributing changes in gene expression to direct dipeptide interaction with DNA and histones, reported by the originating group and by a small number of collaborating laboratories, including studies of short peptides in stem cell differentiation and in monocyte and macrophage cell lines. The internal consistency of results within the group is notable, but the lack of external replication is a major limitation. Claims of anti-aging or immune benefit in humans should therefore be regarded as unproven. Compared with its siblings in the same Khavinson tradition, vilon sits at the least developed end: thymalin and cortexin at least have registered clinical use and observational human reports in Russia, and Cerebrolysin, an unrelated animal-tissue peptide preparation, has enough independent randomized trials to have been assessed twice by Cochrane. Vilon has none of that. There is no published modern toxicology dossier, no human pharmacokinetic data, and no regulatory dossier available for external review.

Documented safety data are limited to short rodent studies, in which investigators reported no overt adverse effects at the doses tested; this is not a substitute for human safety characterization. There are no published human toxicology, drug-interaction, long-term, or reproductive-safety data. Theoretical concerns include the broad and context-dependent roles of NNMT and NAD+/SAM metabolism across tissues (liver, cancer, vasculature), the unknown consequences of chronically altering one-carbon/methylation flux, and the unverified purity and identity of material sold as a "research chemical." Because human safety is essentially uncharacterized, it should be regarded as an experimental compound of unknown human risk.

In the animal studies reported by its developers, vilon appears to be well tolerated at the doses tested, with low toxicity described. However, there is no meaningful independent human safety data, no long-term human studies, and no regulatory safety review outside its originating context. Because no human trial has been conducted, there is no adverse-event table to consult: statements that vilon is safe in people are assertions rather than findings. The absence of a published modern toxicology package is the specific gap that matters, since a regulator would expect repeat-dose toxicity in two species, genotoxicity testing, reproductive toxicity, local tolerance at the injection site, and immunogenicity assessment before any first-in-human study. None of that is available in the indexed literature. The identity and purity of material sold as vilon for research use are not guaranteed, and lyophilized vials distributed through research-chemical channels are not manufactured to pharmaceutical standards, are not tested for sterility or bacterial endotoxin, and may differ from the labeled peptide in content or purity. Injecting a non-sterile preparation carries the ordinary hazards of contamination, including local infection and systemic febrile reactions. A compound proposed to alter gene expression and immune cell behavior also warrants caution in anyone with a history of malignancy or autoimmune disease, a question that has never been addressed experimentally in humans. This is educational information only and not medical or dosing advice.

5-Amino-1MQ is not approved by the FDA (or any major regulator) for any indication and is not a recognized dietary supplement; it is an investigational/research-use-only compound with no publicly documented IND or registered human clinical trials. It is not, as of this writing, a WADA-listed prohibited substance by name, though its NAD+/metabolic mechanism is the kind of area anti-doping bodies monitor.

Vilon is not approved as a drug by the US FDA, the European Medicines Agency, or other major Western regulators, and it is not a dietary supplement. It is sold and used only as a research chemical, and human clinical use is not sanctioned in the US.